Nindl I, Lotz B, Kühne-Heid R, Endisch U, Schneider A
Department of Gynaecology, Friedrich Schiller University, Jena, Germany.
J Clin Pathol. 1999 Jan;52(1):17-22. doi: 10.1136/jcp.52.1.17.
To evaluate the presence of high risk human papillomaviruses (HPV) in cervical smears showing intraepithelial neoplasia (CIN).
The presence of 14 high risk HPV was evaluated in 114 cervical smears with CIN of different degrees, by comparing a non-radioactive polymerase chain reaction (PCR) enzyme immunoassay (EIA) with conventional PCR followed by radioactive Southern blot hybridisation. General primer PCR amplicons detecting low risk and high risk HPV were typed for 14 different high risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) by a non-radioactive PCR-EIA. Virus load of HPV 16 positive CIN was assessed using the semiquantitative PCR-EIA.
Histological evaluation confirmed CIN I in 49 cases (mean age 29.0 years, range 17 to 52), CIN II in 31 cases (mean age 30.8 years, 18 to 54), and CIN III in 34 cases (mean age 31.1 years, 16 to 57). The non-radioactive PCR-EIA showed an overall agreement rate of 90% (kappa value 0.75) when compared with conventional general primer PCR followed by radioactive Southern blot hybridisation. High risk HPVs were detected in 47% of CIN I, 77% of CIN II, and 97% of CIN III (p < or = 0.02). HPV types 39, 51, 56, and 58 were found in CIN I exclusively (between 2% and 8%). HPV 16 and HPV 31 were detected in 12% and 2% of CIN I, 35% and 21% of CIN II, and 74% and 13% of CIN III, respectively (p < or = 0.03 and p < or = 0.04). The virus load estimated by the semiquantitative PCR-EIA of HPV 16 was similar in CIN I, CIN II, and CIN III.
The PCR-EIA has high clinical sensitivity for detecting CIN II/III (90%). There was a significantly higher prevalence rate of HPV 16 and 31 in CIN III than in CIN I and II.
评估显示上皮内瘤变（CIN）的宫颈涂片样本中高危型人乳头瘤病毒（HPV）的存在情况。
通过将非放射性聚合酶链反应（PCR）酶免疫测定（EIA）与传统PCR及放射性Southern印迹杂交相比较，评估114例不同程度CIN的宫颈涂片样本中14种高危型HPV的存在情况。采用非放射性PCR-EIA对检测低危型和高危型HPV的通用引物PCR扩增产物进行14种不同高危型HPV（HPV 16、18、31、33、35、39、45、51、52、56、58、59、66和68）的分型。使用半定量PCR-EIA评估HPV 16阳性CIN的病毒载量。
组织学评估确诊49例为CIN I（平均年龄29.0岁，范围17至52岁），31例为CIN II（平均年龄30.8岁，18至54岁），34例为CIN III（平均年龄31.1岁，16至57岁）。与传统通用引物PCR及放射性Southern印迹杂交相比，非放射性PCR-EIA的总体符合率为90%（kappa值0.75）。在47%的CIN I、77%的CIN II和97%的CIN III中检测到高危型HPV（p≤0.02）。仅在CIN I中发现HPV 39、51、56和58型（2%至8%）。HPV 16和HPV 31分别在12%和2%的CIN I、35%和21%的CIN II以及74%和13%的CIN III中检测到（p≤0.03和p≤0.04）。HPV 16的半定量PCR-EIA估计的病毒载量在CIN I、CIN II和CIN III中相似。
PCR-EIA检测CIN II/III具有较高的临床敏感性（90%）。CIN III中HPV 16和31的患病率显著高于CIN I和II。
